Abattis Announces Vergence Update

Vancouver, British Columbia--(Newsfile Corp. - August 15, 2017) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to provide an update on its wholly-owned subsidiary, Vergence Visionary Bioceuticals ("Vergence"), which is a nutraceutical marketing and brand specialist firm focused on bringing innovative health products to market.

New Brand Partnerships

Vergence has recently signed an agreement to distribute Jonny Hetherington Essentials, a line of all-natural hot sauce and ketchup products. Made entirely from ingredients sourced from British Columbia, Jonny Hetherington Essentials' products are currently sold in over 70 retailers.

Vergence plans to announce new brand partners and products for sales and distribution in local and international markets over the next quarter. In accordance with its business strategy, Vergence will act as sales agent for, and collect commission on, sales of its represented roster of natural health products, paving the way for sales of products formulated in-house by Abattis and its affiliates.

Distribution Website near Completion

Vergence has nearly completed its customized distribution website, which will allow brands carried by Vergence to fulfill orders, manage accounts, and sell their top selling products through the Vergence website.

The aim of the website is to become the "Amazon" for natural health and cannabis products, in terms of variety, availability, recognition and ease of use.

Launch of the website is expected in the coming weeks.

Robert Abenante, President and CEO of Abattis, stated, "Vergence has been given a restart. We've given it its independence to become a sales and distribution leader in the cannabis industry, with the ability to create its own synergistic and complementary entities. Our goal is to have Northern Vine's CBD formulated products distributed and sold through Vergence Naturals."

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

About Northern Vine Canada Inc.

Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.

About Vergence Visionary Bioceuticals Corp.

Vergence, dba Vergence NaturalsTM, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.


"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.


This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "intends", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected timing of announcement of new brands and products for sales and distribution by Vergence; the expected timing of launch of the Vergence website; Vergence's aim to become the "Amazon" for natural health and cannabis products; the Company's plans to sell Northern Vine products through Vergence; Vergence's ability to become a sales and distribution leader in the cannabis industry and the ability to create its own synergistic and complementary entities. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that Vergence may be unable to enter into contracts with owners of the brands and/or products Vergence proposes to distribute on acceptable terms or at all; that the Vergence website may not launch in the time expected or at all; that Vergence may be unable to grow its business to a reasonable commercial scale; that Vergence may be unable to derive profits from its business operations; that Vergence may be unable to scale its business model in order to be the "Amazon" of natural health and cannabis products or to become a sales and distribution and leader in the cannabis industry; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company's competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company's control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.